June 18, 2015
A large, multinational study published in JAIDS reports an increased risk of some cancers for people taking protease inhibitor-based combination antiretroviral therapy (PI-based cART) compared to non-nucleoside reverse transcriptase inhibitor-based cART (NNRTI-based cART). While any successful cART is known to decrease the risk of "AIDS-defining" cancers such as Kaposi sarcoma, the relationship between cART and other cancers has not been well understood.
The D:A:D study -- which included 41,762 participants with HIV from 11 cohorts across Europe, Australia and the United States -- investigated this issue. In this observational study, researchers collected information from participants about any non-AIDS related cancer experienced and antiretroviral treatments used between 2004 and 2012.
A total of 1,832 cancer diagnoses were included in the study: 718 were AIDS-defining cancers, while 1,114 were not. As expected, any type of cART use decreased risk of AIDS-defining cancers. But while use of NNRTI-based cART decreased risk of non-AIDS defining cancers too, exposure to protease inhibitor (PI)-based cART actually seemed to increase risk of non-AIDS defining cancers.
This increased risk associated with PI use -- though small -- may compound and produce a noticeable clinical effect if cART is taken long-term. If there is a causal link between PIs and non-AIDS-defining cancer (which the prospective, observational nature of this study does not prove), the authors say exposure to PIs for five years could result in a 16% increased risk of developing a non-AIDS-defining cancer.
This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.